Lipocine, Inc.
🏢 View company profile →40Patents
25Active
40Granted
51Portfolio score
Filing activity: Feb 26, 1999 → Oct 16, 2020
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6248363A | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions | Emerging Cross-Sectional Technologies | 921 | Expired |
| US6923988B2 | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions | Emerging Cross-Sectional Technologies | 671 | Expired |
| US6383471B1 | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents | Human Necessities | 621 | Expired |
| US6294192A | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents | Performing Operations; Transporting | 610 | Expired |
| US6569463B2 | Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions | Emerging Cross-Sectional Technologies | 603 | Expired |
| US6267985A | Clear oil-containing pharmaceutical compositions | Human Necessities | 432 | Expired |
| US6309663A | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents | Emerging Cross-Sectional Technologies | 338 | Expired |
| US6720001B2 | Emulsion compositions for polyfunctional active ingredients | Emerging Cross-Sectional Technologies | 337 | Expired |
| US6451339B2 | Compositions and methods for improved delivery of hydrophobic agents | Performing Operations; Transporting | 329 | Expired |
| US6761903B2 | Clear oil-containing pharmaceutical compositions containing a therapeutic agent | Performing Operations; Transporting | 234 | Expired |
| US7374779B2 | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents | Human Necessities | 228 | Expired |
| US6468559B1 | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods | Human Necessities | 106 | Expired |
| US6458383B2 | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin | Human Necessities | 89 | Expired |
| US6982281B1 | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs | Human Necessities | 77 | Expired |
| US9034858B2 | High-strength testosterone undecanoate compositions | Physics | 40 | Active |
| US9205057B2 | High-strength testosterone undecanoate compositions | Physics | 37 | Active |
| US8778922B2 | Steroidal compositions | Human Necessities | 36 | Active |
| US8865695B2 | Steroidal compositions | Human Necessities | 32 | Active |
| US9480690B2 | High-strength testosterone undecanoate compositions | Physics | 29 | Active |
| US9358241B2 | High-strength testosterone undecanoate compositions | Human Necessities | 24 | Active |
| US9757390B2 | High-strength testosterone undecanoate compositions | Physics | 23 | Active |
| US9498485B2 | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters | Human Necessities | 23 | Active |
| US8951996B2 | 17-hydroxyprogesterone ester-containing oral compositions and related methods | Human Necessities | 21 | Active |
| US9949985B2 | High-strength testosterone undecanoate compositions | Physics | 18 | Active |
| US10226473B2 | High-strength testosterone undecanoate compositions | Physics | 17 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.